Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 28-Jan-21 7:50 PM View:  | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 26-Jan-21 | Disposition (change in control) | 380,467 | -- | -- | (100%) 380.47K to 0 | |
| 28-Jan-21 7:00 PM View: | Sinha Uma Chief Scientific Officer | Eidos Therapeutics, Inc. (EIDX) | 26-Jan-21 | Disposition (change in control) | 303,525 | -- | -- | (100%) 303.52K to 0 | |
| 28-Jan-21 7:15 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 26-Jan-21 | Disposition (change in control) | 50,699 | -- | -- | (100%) 50.7K to 0 | |
| 15-Jan-21 4:05 PM View: | Sinha Uma Chief Scientific Officer | Eidos Therapeutics, Inc. (EIDX) | 13-Jan-21 | Market Sale (Planned) | 10,000 | $124.32 | $1,243,180.00 | (3%) 316.52K to 306.52K | (3%) |
| 13-Jan-21 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 12-Jan-21 | Option Exercise | 1,747 | $7.24 | $12,648.30 | 100% 0 to 1.75K | |
| 13-Jan-21 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 12-Jan-21 | Market Option Sale | 1,747 | $125.44 | $219,152.00 | (100%) 1.75K to 0 | (2%) |
| 13-Jan-21 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 11-Jan-21 | Option Exercise | 1,500 | $7.24 | $10,860.00 | 100% 0 to 1.5K | |
| 13-Jan-21 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 11-Jan-21 | Market Option Sale | 1,500 | $125.61 | $188,408.00 | (100%) 1.5K to 0 | (2%) |
| 28-Jan-21 7:50 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 28-Dec-20 | Gift | 500 | -- | -- | (< 1%) 380.97K to 380.47K | |
| 16-Dec-20 7:27 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 15-Dec-20 | Market Option Sale | 26,294 | $111.77 | $2,938,800.00 | (34%) 76.92K to 50.62K | (15%) |
| 16-Dec-20 7:27 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 15-Dec-20 | Option Exercise | 26,294 | $13.84 | $363,995.00 | 52% 50.62K to 76.92K | |
| 04-Dec-20 5:34 PM View: | Sinha Uma Chief Scientific Officer | Eidos Therapeutics, Inc. (EIDX) | 02-Dec-20 | Market Sale (Planned) | 5,000 | $90.04 | $450,187.00 | (2%) 321.52K to 316.52K | (43%) |
| 13-Nov-20 5:00 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 11-Nov-20 | Gift | 1,500 | -- | -- | (2%) 65.53K to 64.03K | |
| 13-Nov-20 5:00 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 11-Nov-20 | Market Sale | 13,410 | $74.51 | $999,227.00 | (21%) 64.03K to 50.62K | (72%) |
| 10-Nov-20 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 09-Nov-20 | Market Option Sale | 1,623 | $74.93 | $121,609.00 | (100%) 1.62K to 0 | (71%) |
| 10-Nov-20 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 09-Nov-20 | Option Exercise | 1,623 | $7.24 | $11,750.50 | 100% 0 to 1.62K | |
| 03-Nov-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 02-Nov-20 | Market Option Sale (Planned) | 7,500 | $70.72 | $530,372.00 | (10%) 78.03K to 70.53K | (82%) |
| 03-Nov-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 02-Nov-20 | Option Exercise | 7,500 | $14.47 | $108,500.00 | 11% 70.53K to 78.03K | |
| 03-Nov-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 02-Nov-20 | Market Sale (Planned) | 5,000 | $70.72 | $353,581.00 | (7%) 70.53K to 65.53K | (82%) |
| 30-Oct-20 4:55 PM View: | Sinha Uma Chief Scientific Officer | Eidos Therapeutics, Inc. (EIDX) | 29-Oct-20 | Market Sale (Planned) | 5,000 | $72.42 | $362,099.00 | (2%) 326.52K to 321.52K | (77%) |
| 28-Jan-21 7:00 PM View: | Sinha Uma Chief Scientific Officer | Eidos Therapeutics, Inc. (EIDX) | 27-Oct-20 | Gift | 3,000 | -- | -- | (< 1%) 306.52K to 303.52K | |
| 09-Oct-20 5:23 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 08-Oct-20 | Market Option Sale | 4,755 | $74.85 | $355,917.00 | (91%) 5.2K to 0.44K | (72%) |
| 09-Oct-20 5:23 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 08-Oct-20 | Option Exercise | 5,199 | $7.24 | $37,640.80 | 100% 0 to 5.2K | |
| 09-Oct-20 5:23 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 08-Oct-20 | Market Sale | 444 | $74.85 | $33,233.90 | (100%) 0.44K to 0 | (72%) |
| 09-Oct-20 5:23 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 07-Oct-20 | Market Option Sale | 5,444 | $75.08 | $408,748.00 | (100%) 5.44K to 0 | (71%) |
| 09-Oct-20 5:23 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 07-Oct-20 | Option Exercise | 5,000 | $7.24 | $36,200.00 | 1126% 0.44K to 5.44K | |
| 02-Oct-20 7:43 PM View: | Sinha Uma Chief Scientific Officer Director | Eidos Therapeutics, Inc. (EIDX) | 01-Oct-20 | Market Sale (Planned) | 4,831 | $52.35 | $252,923.00 | (1%) 331.36K to 326.52K | (145%) |
| 02-Oct-20 7:43 PM View: | Sinha Uma Chief Scientific Officer Director | Eidos Therapeutics, Inc. (EIDX) | 30-Sep-20 | Market Sale (Planned) | 169 | $52.03 | $8,793.52 | (< 1%) 331.52K to 331.36K | (147%) |
| 18-Sep-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 17-Sep-20 | Market Sale (Planned) | 5,767 | $50.16 | $289,259.00 | (1%) 386.73K to 380.97K | (156%) |
| 16-Sep-20 6:35 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 16-Sep-20 | Market Sale (Planned) | 3,122 | $50.16 | $156,610.00 | (< 1%) 389.86K to 386.73K | (156%) |
| 16-Sep-20 6:35 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 15-Sep-20 | Market Sale (Planned) | 1,000 | $50.06 | $50,064.00 | (< 1%) 390.86K to 389.86K | (157%) |
| 16-Sep-20 6:35 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 14-Sep-20 | Market Sale (Planned) | 111 | $50.00 | $5,550.00 | (< 1%) 390.97K to 390.86K | (157%) |
| 11-Sep-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 10-Sep-20 | Option Exercise | 2,500 | $17.00 | $42,500.00 | 4% 70.53K to 73.03K | |
| 11-Sep-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 10-Sep-20 | Market Option Sale (Planned) | 2,500 | $47.00 | $117,500.00 | (3%) 73.03K to 70.53K | (173%) |
| 05-Aug-20 7:45 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 03-Aug-20 | Market Option Sale (Planned) | 5,000 | $39.94 | $199,725.00 | (6%) 80.53K to 75.53K | (222%) |
| 05-Aug-20 7:45 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 03-Aug-20 | Market Sale (Planned) | 5,000 | $39.94 | $199,725.00 | (7%) 75.53K to 70.53K | (222%) |
| 05-Aug-20 7:45 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 03-Aug-20 | Option Exercise | 5,000 | $13.20 | $66,000.00 | 7% 75.53K to 80.53K | |
| 09-Jul-20 4:05 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 07-Jul-20 | Market Sale (Planned) | 5,000 | $50.00 | $250,000.00 | (1%) 395.97K to 390.97K | (157%) |
| 01-Jul-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 29-Jun-20 | Acquisition (other) | 1,088 | -- | -- | < 1% 394.88K to 395.97K | |
| 05-Jun-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 03-Jun-20 | Market Sale (Planned) | 5,000 | $50.00 | $250,000.00 | (1%) 399.88K to 394.88K | (157%) |
| 05-Jun-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 02-Jun-20 | Gift | 1,020 | -- | -- | (< 1%) 400.9K to 399.88K | |
| 05-Jun-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 01-Jun-20 | Gift | 1,020 | -- | -- | (< 1%) 401.92K to 400.9K | |
| 05-Jun-20 4:06 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 31-May-20 | Grant | 444 | $41.57 | $18,458.60 | < 1% 401.48K to 401.92K | |
| 05-Jun-20 4:05 PM View: | Sinha Uma Chief Scientific Officer Director | Eidos Therapeutics, Inc. (EIDX) | 31-May-20 | Grant | 444 | $41.57 | $18,458.60 | < 1% 331.08K to 331.52K | |
| 05-Jun-20 4:06 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 31-May-20 | Grant | 376 | $41.57 | $15,631.60 | < 1% 75.16K to 75.53K | |
| 05-Jun-20 4:05 PM View: | Valle Franco Senior Vice President, Finance | Eidos Therapeutics, Inc. (EIDX) | 31-May-20 | Grant | 444 | $41.57 | $18,458.60 | 100% 0 to 0.44K | |
| 01-Jun-20 4:05 PM View: | Fox Jonathan C See Remarks | Eidos Therapeutics, Inc. (EIDX) | 28-May-20 | Market Sale (Planned) | 5,000 | $50.00 | $250,000.00 | (1%) 406.48K to 401.48K | (157%) |
| 28-May-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 26-May-20 | Option Exercise | 2,500 | $17.00 | $42,500.00 | 3% 75.16K to 77.66K | |
| 28-May-20 4:05 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 26-May-20 | Market Option Sale (Planned) | 2,500 | $47.00 | $117,500.00 | (3%) 77.66K to 75.16K | (173%) |
| 05-May-20 4:26 PM View: | Turtle Cameron Chief Business Officer | Eidos Therapeutics, Inc. (EIDX) | 01-May-20 | Option Exercise | 5,000 | $13.20 | $66,000.00 | 6% 80.16K to 85.16K |
